Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Business Overview: Gilead is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for infectious diseases, primarily HIV, Hepatitis B, and Hepatitis C. Key products include Truvada, Viread, Emtriva, Hepsera, AmBisome, and Vistide. The company also holds significant royalty interests in Tamiflu (marketed by Roche) and Macugen (marketed by OSI Pharmaceuticals).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2006 |
Three Months Ended June 30, 2005 |
Six Months Ended June 30, 2006 |
Six Months Ended June 30, 2005 |
|---|---|---|---|---|
| Total Revenues | $685,302 | $495,269 | $1,378,180 | $925,683 |
| Net Income | $265,150 | $195,967 | $527,854 | $353,080 |
| Diluted EPS | $0.56 | $0.41 | $1.10 | $0.75 |
| Operating Cash Flow | N/A | N/A | $487,793 | $516,032 |
| Cash & Marketable Securities | $3,299,666 | N/A | $3,299,666 | $2,311,033 |
| Working Capital | $1,983,901 | N/A | $1,983,901 | $2,627,045 |
| Convertible Senior Notes | $1,300,000 | $0 | $1,300,000 | $0 |
Note: Cash and marketable securities increased significantly in Q2 2006 due to the issuance of convertible notes and reclassification of long-term securities.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 38% year-over-year for the quarter and 49% for the six-month period. This was driven by a 38% increase in HIV product sales (led by Truvada) and a 102% increase in royalty and contract revenue (primarily Tamiflu royalties).
- Product Mix: Truvada sales surged 143% year-over-year to $299.3 million, while Viread sales declined 20% to $167.4 million as patients switched to the combination therapy. Hepsera sales grew 24%.
- Expense Increases: Operating expenses rose significantly due to the adoption of SFAS 123R (stock-based compensation), which added $36.8 million in expenses for the quarter. R&D expenses increased 52% and SG&A expenses increased 60% compared to the prior year quarter.
- Capital Structure: In April 2006, the company issued $1.3 billion in convertible senior notes (due 2011 and 2013) and repurchased $544.9 million of common stock.
- Accounting Changes: The company adopted SFAS 123R on January 1, 2006, requiring the expensing of stock-based compensation, which materially impacted reported net income and operating margins.
Guidance, Outlook, and Risks
- 2006 Revenue Guidance:
- HIV Products (including Atripla): $1.95 billion to $2.00 billion.
- AmBisome: $205.0 million to $215.0 million.
- Hepsera: $215.0 million to $225.0 million.
- 2006 Expense Guidance:
- R&D Expenses: $345.0 million to $370.0 million.
- SG&A Expenses: $550.0 million to $580.0 million.
- Effective Tax Rate: 33% to 35%.
- Key Developments:
- Atripla Launch: Received FDA approval in July 2006 for the single-tablet regimen of Truvada and Sustiva (joint venture with BMS).
- Acquisitions: Agreed to acquire Raylo Chemicals Inc. (approx. $144.3 million) and Corus Pharma Inc. (approx. $365.0 million option exercise).
- Product Pipeline: Dosed first patient in Phase 2 study for integrase inhibitor GS 9137.
- Risks and Contingencies:
- Legal: Pending litigation regarding Medicaid pricing (five cases) and an appealed dismissal of a securities class action lawsuit.
- Regulatory: Risks related to compulsory licensing in developing countries (e.g., Brazil) and generic competition.
- Operational: Dependence on third-party manufacturers and distributors; potential integration risks with pending acquisitions.
- Financial: Exposure to foreign currency fluctuations (Euro) and credit risk from European government customers.
Investor Verification Checklist
- Stock-Based Compensation Impact: Verify the sustainability of margins given the significant one-time and recurring impact of SFAS 123R adoption on operating expenses.
- Atripla Commercialization: Monitor the launch performance of Atripla and its cannibalization effect on standalone Truvada and Viread sales.
- Acquisition Integration: Assess the financial impact and integration progress of the pending Raylo and Corus acquisitions, including potential charges for in-process R&D.
- European Receivables: Review the aging of accounts receivable from European government customers (noted at $276.4 million) and potential payment delays.
- Convertible Note Dilution: Evaluate the potential dilution from the $1.3 billion convertible notes, noting the conversion prices ($77.50 and $76.20) and the associated warrant/hedge structures.
- Tamiflu Royalty Volatility: Confirm the sustainability of royalty revenue from Roche, which is highly dependent on global pandemic planning and sales volumes.